Proteros obtains CIR accreditation that allows eligible clients to receive 30% of their R&D costs in tax credits
Martinsried February 24, 2012. Proteros biostructures GmbH (“Proteros”) a leading provider of structure-based drug discovery services announced today that it has been awarded CIR accreditation by the French Ministry of Higher Education and Research. The accreditation allows eligible French companies to benefit from significant tax relief (Crédit d’Impôt sur la Recherche) on research carried out by Proteros on their behalf until 2013.
“We are very pleased that our French clients will be able to benefit from the CIR accreditation and the opportunity to receive 30% of their R&D costs in tax credits” said Gordon Woodrow, EVP Strategic Alliances. “Proteros’ clients can access services that range from protein crystallography, kinetic/thermodynamic profiling and custom proteins to fully integrated structure-based lead discovery including proprietary protein-inspired fragment libraries and medicinal chemistry.”
Proteros is a privately held company that provides services and proprietary technologies to support integrated drug discovery. The company accelerates and improves protein structure analysis and structure-based drug discovery with its expertise, industrialized processes and unique technologies for crystallography and fragment-based lead generation. Proteros complements its clients’ internal capabilities with external expertise and access to flexible resources. Proteros currently provides services for more than 60 pharmaceutical and biotechnology clients in North America, Europe and Asia.
For further information please visit the website at: www.proteros.com